The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat
- PMID: 14622685
- DOI: 10.1016/s1526-5900(03)00618-7
The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat
Abstract
Preliminary reports have demonstrated that the application of local heat to the transdermal fentanyl patch significantly increased systemic delivery of fentanyl. The objective of this study was to further evaluate the pharmacokinetic effect of local heat administration on fentanyl drug delivery through the transdermal fentanyl patch delivery system in volunteers. In addition, the study was intended to document the effect of heat on steady-state transdermal fentanyl delivery. This was an open, 3-period, crossover study that evaluated the pharmacokinetics and safety of 25 microg/h transdermal fentanyl administered with and without local heat. During Sessions A and B, subjects received transdermal fentanyl for a 30-hour period. During Session A, heat was applied for 1 hour at the 24-hour time point during the 30-hour period. During Session B, heat was applied for the first 4 hours and then again for 1 hour at the 24-hour time point during the 30-hour period. The order of Sessions A and B was randomized, and a minimum of 2 weeks separated the sessions. Five of the 10 subjects returned to participate in Session C. During Session C, subjects received transdermal fentanyl 25 microg/h for 18 hours. Heat was applied during the first 4 hours of administration and then again for 15-minute periods at the 12- and 16-hour time points. Arterial blood samples for determination of serum fentanyl concentration were collected. Maximum concentration (C(max)), time to maximum concentration (t(max)), and area under the curve (AUC) were determined for each treatment period. Sedation, vital signs, oxygen saturation, and adverse events were recorded. During a period of 36 hours, there were no significant differences in C(max), AUC, or T(max) between transdermal fentanyl delivery with no heat and heat. However, significant differences were seen during the first 4 hours, with C(max) and AUC values almost 3 times higher for the heated administrations than for the administrations without heat. With heat, the mean C(max) was 0.63 ng/mL compared with a C(max) of 0.24 ng/mL without heat (P =.007). With early heat, the mean AUC was 1.22 ng/mL. h compared with 0.42 ng/mL. h without heat (P =.003). There was no statistically significant difference between the median times to achieve peak values (T(max)) during the first 4 hours. The addition of heat at 24 hours resulted in rapid increases in serum fentanyl concentrations for both groups and higher serum fentanyl concentrations for the administration that did not receive heat previously. Applying heat for 15 minutes at the 12-hour and 16-hour time points produced a rapid but short duration increase in serum fentanyl concentrations. The results suggest controlled heat might be used to significantly shorten the time needed to reach clinically important fentanyl concentrations. Controlled heat might be useful to produce rapid increases in serum concentrations for the rapid treatment of breakthrough pain.
Similar articles
-
Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.Clin Ther. 2006 May;28(5):715-24. doi: 10.1016/j.clinthera.2006.05.016. Clin Ther. 2006. PMID: 16861093 Clinical Trial.
-
Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration.Clin Pharmacokinet. 2005;44 Suppl 1:7-15. doi: 10.2165/00003088-200544001-00003. Clin Pharmacokinet. 2005. PMID: 16156111 Clinical Trial.
-
Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS).Clin Pharmacokinet. 2005;44 Suppl 1:25-32. doi: 10.2165/00003088-200544001-00005. Clin Pharmacokinet. 2005. PMID: 16156113 Clinical Trial.
-
Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.Clin Pharmacokinet. 2000 Jan;38(1):59-89. doi: 10.2165/00003088-200038010-00004. Clin Pharmacokinet. 2000. PMID: 10668859 Review.
-
Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.Drugs. 1997 Jan;53(1):109-38. doi: 10.2165/00003495-199753010-00011. Drugs. 1997. PMID: 9010652 Review.
Cited by
-
Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions.J Diabetes Sci Technol. 2012 Jul 1;6(4):780-5. doi: 10.1177/193229681200600407. J Diabetes Sci Technol. 2012. PMID: 22920802 Free PMC article. Review.
-
Life-threatening coma and full-thickness sunburn in a patient treated with transdermal fentanyl patches: a case report.J Med Case Rep. 2012 Jul 26;6:220. doi: 10.1186/1752-1947-6-220. J Med Case Rep. 2012. PMID: 22835002 Free PMC article.
-
Formulations of fentanyl for the management of pain.Drugs. 2010;70(1):57-72. doi: 10.2165/11531740-000000000-00000. Drugs. 2010. PMID: 20030425
-
Effect of Controlled Heat Application on Topical Diclofenac Formulations Evaluated by In Vitro Permeation Tests (IVPT) Using Porcine and Human Skin.Pharm Res. 2020 Feb 7;37(3):49. doi: 10.1007/s11095-019-2741-1. Pharm Res. 2020. PMID: 32034502
-
Health Risks and Interventions in Exertional Heat Stress.Dtsch Arztebl Int. 2019 Aug 5;116(31-32):537-544. doi: 10.3238/arztebl.2019.0537. Dtsch Arztebl Int. 2019. PMID: 31554541 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical